CRBP
Corbus Pharmaceuticals Holding
7.70$
+2.3%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 99.0% | 98.8% | 97.3% | 97.8% | 94.1% | 77.6% | 90.0% | 93.0% | 90.8% | 83.3% | 98.1% | 99.3% | |
| 94.9% | 95.8% | 83.8% | 93.4% | 88.8% | 64.6% | 83.5% | 23.2% | 25.6% | 48.5% | 11.0% | 16.9% | |
| 94.9% | 95.8% | 83.8% | 93.4% | 88.8% | 64.6% | 83.5% | 90.6% | 89.3% | 73.9% | 95.6% | 97.5% | |
| 20.2% | – | 7.4% | – | – | 5.5% | 2.5% | – | – | – | – | 0.9% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | -5.5% | 0.3% | – | – | – | – | – | |
| 0.8% | 1.0% | 2.4% | 2.1% | 5.8% | 10.3% | 9.1% | 6.5% | 8.3% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 11.2% | 30.2% | 50.1% | 13.7% | 41.4% | 87.5% | 55.7% | 35.9% | 50.3% | 124.4% | 8.6% | 12.3% | |
| 11.2% | 28.2% | 49.7% | 12.2% | 38.5% | 71.0% | 31.2% | 15.8% | 19.1% | 112.8% | 7.6% | 12.3% | |
| 2.2% | -3.1% | 1.5% | 0.5% | 0.8% | 2.7% | 1.7% | 4.6% | 6.7% | 62.4% | 1.0% | 1.0% | |
| 5.2% | 10.2% | 19.1% | 4.7% | 13.5% | 22.6% | 7.2% | 1.7% | 3.3% | 11.2% | 3.1% | 1.3% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | 17.6% | 14.5% | 24.1% | – | – | – | |
| 88.8% | 69.8% | 49.9% | 86.3% | 58.6% | 12.5% | 44.3% | 64.1% | 49.7% | -24.4% | 91.4% | 87.7% | |
| -67.1% | -103.1% | -186.0% | -98.1% | -258.3% | -392.4% | -297.3% | -324.6% | -591.3% | -1,544.6% | -305.9% | -330.2% | |
| 10.2% | 8.1% | 7.7% | 2.5% | 4.0% | 4.3% | 2.5% | 3.8% | 6.3% | 15.3% | 7.0% | 7.9% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.